Can a shorter radiation course for prostate cancer be just as safe?
NCT ID NCT05820633
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 3 trial compares a new, shorter course of radiation (ultra-hypofractionated) to the standard longer course for men with prostate cancer that has spread to lymph nodes. Both groups also receive a brachytherapy boost and hormone therapy. The study aims to see if the shorter treatment causes similar side effects and maintains quality of life. 500 participants are planned, but the trial is currently suspended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiotherapy (ultra-hypofractionated pelvic IMRT with HDR brachytherapy boost)
What this could lead to
If successful, this could show that a shorter course of radiation is just as safe and effective as the standard longer course for prostate cancer patients.
What could go wrong
This trial is currently suspended, so results may be delayed or not happen. It is a non-inferiority study, meaning it aims to prove the new approach is not worse than the standard, not necessarily better. Side effects from radiation remain a risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BC Cancer Sindi Ahluwalia centre for the Southern Interior
Kelowna, British Columbia, V1Y 5L3, Canada
-
CHU de Québec - Université Laval
Québec, G1R 2J6, Canada
-
CISSS de Laval, Hôpital de la Cité-de-la-Santé
Laval, Quebec, H7M 3L9, Canada
-
CISSS de l'Outaouais, Hôpital de Gatineau
Gatineau, Quebec, J8P 7H2, Canada
-
CISSS de la Montérégie-Centre, Hôpital Charles-Le Moyne
Longueuil, Quebec, J4V 2H1, Canada
-
CIUSSS de l'Est-de-l'Île-de-Montréal, Hôpital Maisonneuve-Rosemont
Montreal East, Quebec, H1T 2M4, Canada
-
CIUSSS de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CHUS)
Sherbrooke, Quebec, Canada
-
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal, Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
Carlo Fidani Peel Regional Cancer Centre
Mississauga, Ontario, L5M 2N1, Canada
-
Cedars Cancer Centre, McGill University Health Centre (MUHC)
Montreal, Quebec, H4A 3J1, Canada
-
Lakeridge Health Oshawa Cancer centre
Oshawa, Ontario, L1G 2B9, Canada